Research Article

Development and progression of myopia in emmetropic children in Turkey

Volume: 4 Number: 5 October 27, 2023
TR EN

Development and progression of myopia in emmetropic children in Turkey

Abstract

Aims: To investigate the development and progression of myopia in emmetrope school-aged children in Turkey. Methods: This retrospective study included emmetrope children aged 6-18 who attended the ophthalmology clinic for regular eye and refractive examinations between 2010 and 2021. Individuals were examined at least twice for six months period. Myopia progression was calculated as the difference between the baseline and the last visit spherical equivalent refractive (SER) values. Individuals were further categorized to determine the age-specific myopia development and progression as 6-11, 12-16, and 17-18 age groups based on the school periods of the country. According to the change in SER values, individuals were classified into those who remain emmetrope and those who develop myopia. Results: A total of 738 eyes of 369 children (222 female, 147 male) with a mean age of 9.4 ± 2.98 (6-18) years were included in the study. The mean follow-up time of patients was 45.62 ± 26.36 (6-130) months. The baseline mean SER value was -0.01 ± 0.10 D (range: -0.375 and +0.375) and -0.44 ± 0.8 (range: -5.00 and +0.375) at the final visit. The overall mean progression was -0.12 ± 0.25 D/year (range: -2.21 and +0.36). 234 eyes (31.75%) developed myopia, and annual SER change was -0.38 ± 0.31 D/year (p<0.001). 79 (35.7%) of females and 38 (25.9%) of males developed myopia with a statistical significance (p<0.006). There were 163 children between 6–11 years, 169 children between 12-16 years, 37 children between 17-18 years, and 41 (25.2%), 69 (40.8%), and 7 (18.9%) patients of age groups developed myopia, respectively (p=0.15). Conclusion: The development and progression of myopia is more common in 12-16 ages and females. Myopia prevention recommendations should be carefully advised to predisposed age populations and females to reduce myopia progression.

Keywords

References

  1. Myopia J, Mariotti S, Kocur I, et al. The impact of myopia and high myopia. Report of the Joint World Health Organization-Brien Holden Vision Institute Global Scientific Meeting on Myopia, 2015.
  2. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-42. https://doi.org/10.1016/j.ophtha. 2016.01.006
  3. Morgan IG, French AN, Ashby RS, et al. The epidemics of myopia: Aetiology and prevention. Prog Retin Eye Res. 2018;62:134-149. doi:10.1016/j.preteyeres.2017.09.004
  4. Iribarren R, Cortinez MF, Chiappe JP. Age of first distance prescription and final myopic refractive error. Ophthalmic Epidemiol. 2009;16(2):84-9. doi: 10.1080/09286580802624442. PMID: 19353396.
  5. Ohno-Matsui K, Wu PC, Yamashiro K, et al. IMI Pathologic Myopia [published correction appears in Invest Ophthalmol Vis Sci. 2021;62(7):17]. Invest Ophthalmol Vis Sci. 2021;62(5):5. doi:10.1167/iovs. 62.5.5
  6. French AN, Ashby RS, Morgan IG, Rose KA. Time outdoors and the prevention of myopia. Exp Eye Res. 2013;114:58-68. doi:10.1016/j.exer.2013.04.018
  7. McCullough SJ, O’Donoghue L, Saunders KJ. Six year refractive change among white children and young adults: evidence for significant ıncrease in myopia among white UK children. PLoS One. 2016;11(1):e0146332. doi:10.1371/journal.pone.0146332
  8. Villarreal MG, Ohlsson J, Abrahamsson M, Sjöstrom A, Sjöstrand J. Myopisation: the refractive tendency in teenagers. Prevalence of myopia among young teenagers in Sweden. Acta Ophthalmol Scand. 2000;78(2):177-181. doi:10.1034/j.1600-0420.2000.078002177.x

Details

Primary Language

English

Subjects

Vision Science

Journal Section

Research Article

Early Pub Date

October 26, 2023

Publication Date

October 27, 2023

Submission Date

August 13, 2023

Acceptance Date

August 28, 2023

Published in Issue

Year 2023 Volume: 4 Number: 5

APA
Kaya, P. (2023). Development and progression of myopia in emmetropic children in Turkey. Journal of Medicine and Palliative Care, 4(5), 380-384. https://doi.org/10.47582/jompac.1342383
AMA
1.Kaya P. Development and progression of myopia in emmetropic children in Turkey. J Med Palliat Care / JOMPAC / jompac. 2023;4(5):380-384. doi:10.47582/jompac.1342383
Chicago
Kaya, Pınar. 2023. “Development and Progression of Myopia in Emmetropic Children in Turkey”. Journal of Medicine and Palliative Care 4 (5): 380-84. https://doi.org/10.47582/jompac.1342383.
EndNote
Kaya P (October 1, 2023) Development and progression of myopia in emmetropic children in Turkey. Journal of Medicine and Palliative Care 4 5 380–384.
IEEE
[1]P. Kaya, “Development and progression of myopia in emmetropic children in Turkey”, J Med Palliat Care / JOMPAC / jompac, vol. 4, no. 5, pp. 380–384, Oct. 2023, doi: 10.47582/jompac.1342383.
ISNAD
Kaya, Pınar. “Development and Progression of Myopia in Emmetropic Children in Turkey”. Journal of Medicine and Palliative Care 4/5 (October 1, 2023): 380-384. https://doi.org/10.47582/jompac.1342383.
JAMA
1.Kaya P. Development and progression of myopia in emmetropic children in Turkey. J Med Palliat Care / JOMPAC / jompac. 2023;4:380–384.
MLA
Kaya, Pınar. “Development and Progression of Myopia in Emmetropic Children in Turkey”. Journal of Medicine and Palliative Care, vol. 4, no. 5, Oct. 2023, pp. 380-4, doi:10.47582/jompac.1342383.
Vancouver
1.Pınar Kaya. Development and progression of myopia in emmetropic children in Turkey. J Med Palliat Care / JOMPAC / jompac. 2023 Oct. 1;4(5):380-4. doi:10.47582/jompac.1342383

TR DİZİN ULAKBİM and International Indexes (1d)

Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS]
 


 

download?token=eyJhdXRoX3JvbGVzIjpbXSwiZW5kcG9pbnQiOiJqb3VybmFsIiwib3JpZ2luYWxuYW1lIjoiVHJfSW5kZXhfbG9nby5wbmciLCJwYXRoIjoiN2EzMC84NTVhL2UyMWMvNjlkZjRkZmVhNTUyNTYuNzg3NjU2ODgucG5nIiwiZXhwIjoxNzc2MjQ1Nzc0LCJub25jZSI6IjU0MDZkMWE2NmE1Y2QwZTJjNGYyNDA1OTM2MTE0YWIxIn0.Tt-WScFXTj5r2jji5eDMFApNzujLMjMPl8ivXRbozSI



f9ab67f.png
asos-index.png


 


download?token=eyJhdXRoX3JvbGVzIjpbXSwiZW5kcG9pbnQiOiJqb3VybmFsIiwib3JpZ2luYWxuYW1lIjoiQ3Jvc3NyZWYuanBnIiwicGF0aCI6IjAzMzEvMTdkZi8yN2ZkLzY5ZGY0ZThhMDZkMjg0LjQxMjAyNDg5LmpwZyIsImV4cCI6MTc3NjI0NTkxNCwibm9uY2UiOiI2NjM1Yjc5MWFiY2I1MDQ0NjkzMTAxMDhjY2Y2NzRlMCJ9.5jDQBEY-KErkDK1QjDmv9ichOkNIn5CWYibe1Wz1644
icmje_1_orig.png
 
cc.logo.large.png
 
ncbi.png
 
google-scholar.pngpn6krf5.jpg
 


 

Our journal is in TR-Dizin, DRJI (Directory of Research Journals Indexing, General Impact Factor, Google Scholar, Researchgate, CrossRef (DOI), ROAD, ASOS Index, Turk Medline Index, Eurasian Scientific Journal Index (ESJI), and Turkiye Citation Index.

EBSCO, DOAJ, OAJI and ProQuest Index are in process of evaluation. 

 

Journal articles are evaluated as "Double-Blind Peer Review"